Caption Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Caption Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.3M	Sell	110,000 -109,500	-50%	-$2.47M	0.01%	786
2025 Q4	$5.05M	Buy	219,500 +54,999	+33%	+$1.81M	0.03%	515
2025 Q3	$4.95M	Sell	164,501 -72,999	-31%	-$2.19M	0.04%	490
2025 Q2	$8.64M	Buy	237,500 +58,672	+33%	+$2.12M	0.1%	248
2025 Q1	$6.48M	Buy	178,828 +61,257	+52%	+$2.55M	0.06%	308
2024 Q4	$4.95M	Buy	117,571 +108,971	+1,267%	+$5.41M	0.05%	377
2024 Q3	$478K	Buy	+8,600	New	+$438K	0.01%	933
2023 Q2	–	Sell	-18,024	Closed	-$836K	–	1344
2023 Q1	$723K	Buy	18,024 +12,524	+228%	+$537K	0.01%	699
2022 Q4	$255K	Sell	5,500 -46,300	-89%	-$1.82M	﹤0.01%	1032
2022 Q3	$2.15M	Buy	51,800 +51,766	+152,253%	+$2.66M	0.03%	617
2022 Q2	$2K	Buy	+34	New	+$2.09K	﹤0.01%	1389
2021 Q2	–	Sell	-10,801	Closed	-$1.23M	–	1521
2021 Q1	$1.23M	Buy	+10,801	New	+$1.47M	0.03%	640

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Caption Management's RARE Position: Q1 2026 in Review

Caption Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 50% in Q1 2026, selling an estimated $2.47M and leaving 110,000 shares worth $2.3M. The position accounts for 0.01% of the portfolio, ranked #786.

Caption Management first reported a position in RARE in Q1 2021 and has held it in 12 quarters since. The position peaked at $8.64M in Q2 2025. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Caption Management held 110,000 shares of Ultragenyx Pharmaceutical worth $2.3M as of Q1 2026.
Caption Management sold 109,500 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $2.47M.
Ultragenyx Pharmaceutical made up 0.01% of Caption Management's portfolio in Q1 2026, its #786 holding.
Caption Management first reported a position in Ultragenyx Pharmaceutical in Q1 2021 and has held it in 12 quarters since.
Caption Management's Ultragenyx Pharmaceutical position peaked at $8.64M in Q2 2025.
296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.